Key result
Low circulating adiponectin levels were significantly and inversely associated with left ventricular mass index (P<0.0001) and a higher prevalence of cardiometabolic comorbidities.
Why the study?
Is low circulating adiponectin associated with increased left ventricular mass and cardiometabolic comorbidities in subjects at high cardiovascular risk?
Cross-Sectional (n=115)
Is low circulating adiponectin associated with increased left ventricular mass and cardiometabolic comorbidities in subjects at high cardiovascular risk?
p-value: p=<0.0001
Circulating adiponectin is independently associated with left ventricular mass index and cardiometabolic comorbidities, suggesting its potential as a marker for global cardiovascular risk.
OBJECTIVE: This study was designed to evaluate the relationship among circulating adiponectin (ADPN), left ventricular mass (LVM) and cardio-metabolic comorbidities in subjects at higher global cardiovascular risk (score of"Cuore Project"). METHODS: 115 consecutive subjects were grouped according to normal or low ADPN levels. Left ventricular internal diameter (LVID/h), total LV mass (LVM), LVM index (LVMI), relative wall thickness (RWT), LV ejection fraction by echocardiography and diastolic parameters, by pulsed-wave Doppler were calculated. RESULTS: Low-ADPN subjects were characterized by a significantly higher prevalence of some cardiometabolic comorbidities (obesity, visceral obesity, diabetes and insulin resistance, LVH, metabolic syndrome (MetS), coronary artery syndrome (CAD). BMI (P < 0.0001), WHR (P < 0.03), trigly cerides (P < 0.001), HOMA-IR (P < 0.001), LVM, LVMI, IVST and RWT (P < 0.0001) were significantly higher and HDL-C (P < 0.001) and LVEF were significantly lower in low-ADPN than in normal-ADPN subjects. LVMI correlated directly with BMI (P < 0.001), WHR (P < 0.001) MBP (P < 0.001), MetS (P < 0.001) and inversely with ADPN (P < 0.0001). Multiple regres- sion analysis indicated that ADPN was independently associated with LVMI. CONCLUSIONS: ADPN might be considered a key component mediating the cross-talk between adipose tissue, cardiac cells and the vasculature. Accordingly, its routine measurement might become a new target in the management of global CV risk.
No takes yet. Share an insight, caveat, or question.
Chiara et al. (2015) conducted a cross-sectional in Higher global cardiovascular risk (n=115). Low circulating adiponectin (ADPN) levels vs. Normal ADPN levels was evaluated on Left ventricular mass index (LVMI) and cardiometabolic comorbidities (p=<0.0001). Low circulating adiponectin levels were significantly and inversely associated with left ventricular mass index (P<0.0001) and a higher prevalence of cardiometabolic comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: